Clarity Pharmaceuticals Announces the US FDA Grants Rare Paediatric Disease Designation to 64Cu-SARTATE™, a diagnostic for the clinical management of neuroblastoma
SYDNEY, Sept. 9, 2020 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Paediatric Disease Designation (RPDD) to 64Cu-SARTATE™, a diagnostic for the clinical management of...